PBC worst for life quality among autoimmune liver diseases: Study
Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…
News
PFIC Awareness Day means… spotlighting the rare liver disease
Supporters are gearing up for the 7th Annual PFIC Awareness Day on Oct. 5, with advocates behind the yearly event focused on improving public awareness,…
High blood pressure may pose greatest risk of death in MASLD
High blood pressure is a leading cardiometabolic risk factor — a condition linked to problems such as heart disease, stroke, and diabetes — associated with…
7 genes identified as potential biliary atresia treatment targets
Researchers identified seven genes that may contribute to biliary atresia, a discovery that could provide opportunities to develop treatments or biological markers for the…
Program improves hepatitis C treatment access for new moms
A simple shift in where new mothers receive care is helping the fight against hepatitis C. By bringing infectious disease specialists to a mother’s…
Phase 2 trial of volixibat for PSC-related itching now fully enrolled
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…
Newly ID’d LSR gene mutations are likely cause of PFIC in 3 children
Newly identified mutations in the LSR gene were the likely cause of progressive familial intrahepatic cholestasis (PFIC) in three unrelated children — two of whom…
Roche to acquire 89bio, will get pegozafermin for MASH in deal
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
Bylvay now approved in Canada to treat adults, children with Alagille
Bylvay (odevixibat), an oral medication used to treat cholestatic pruritus — severe itching that results from a buildup of bile acids used in digestion —…
FDA OKs clinical trials to test cell therapy for chronic hepatitis B
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
Recent Posts
- An easy transition to new vitamins is a breakthrough for my son
- Too much sorbitol may raise fatty liver disease risk, study finds
- Nebokitug reduces immune cell activity that drives PSC: Data
- New biomarkers may help detect pregnancy-linked liver complication
- Access to food is a survival tactic when your liver needs nutrition